The Federal Circuit's ruling may reshape patent listing practices under Hatch-Waxman, influencing generic drug market access.
The case challenges the suitability of listing device patents in the Orange Book regarding patent claims.
The ruling could define how device patents relate to broader patent strategies for pharmaceuticals.